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Abstract Proliferating myoblasts express MyoD, yet no
phenotypic markers are activated as long as mitogen levels are
sufficient to keep the cells dividing. Depending upon mitogen
levels, a decision is made in G1 that commits the myoblast to
either continue to divide or to exit from the cell cycle and activate
terminal differentiation. Ectopic expression of MyoD under the
control of the RSV or CMV promoters causes 10T1/2 cells to
rapidly exit the cell cycle and differentiate as single myocytes,
even in growth medium, whereas expression of MyoD under the
weaker SV40 promoter is compatible with proliferation. Co-
expression of MyoD and cyclin D1, but not cyclins A, B, E or
D3, blocks transactivation of a MyoD responsive reporter.
Similarly, transfection of myoblasts with the cyclin-dependent
kinase (cdk) inhibitors p16 and p21 supports some muscle-
specific gene expression even in growth medium. Taken
altogether, these results suggest cell cycle progression negatively
regulates myocyte differentiation, possibly through a mechanism
involving the D1 responsive cdks. We review evidence coupling
growth status, the cell cycle and myogenesis. We describe a novel
mitogen-sensitive mechanism that involves the cyclin D1-
dependent direct interaction between the G1 cdks and MyoD in
the dividing myoblast, which regulates MyoD function in a
mitogen-sensitive manner. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Both primary cultures of skeletal muscle as well as estab-
lished muscle cell lines have been used as model systems to
study the processes involved in tissue formation during devel-
opment. The dividing muscle precursor cell or myoblast can
be maintained as a dividing cell that will only form muscle
once growth factors in the medium have been reduced. When
this occurs the myoblast exits the cell cycle in G1 to a G0
state, fuses with adjacent myoblasts to form a syncitial myo-
tube and commences to express the repertoire of skeletal
muscle-speci¢c genes [1]. However, the processes underlying
this regulation have only recently come to light. With the
identi¢cation of the MyoD family of skeletal muscle-speci¢c
gene regulatory proteins, known as MyoD, myogenin, myf-5
and MRF4, the study of myogenesis changed completely (re-
viewed in [2^6]). Committed myoblasts in the somite express
MyoD and myf-5 and mark cells that will eventually give rise
to vertebral muscle as well as cells that have been shown to
migrate from the somite to form portions of the limb muscu-
lature (reviewed in [2,7]). Cultured myoblasts express one or
both of these markers as well. Remarkably, each of these
basic-helix-loop-helix (bHLH) proteins, when ectopically ex-
pressed in a variety of cell types from di¡erent germ layer
origins, can convert non-muscle cells into muscle [8^10].
This result led to the hypothesis that the MyoD family of
genes were involved in determining and maintaining the myo-
genic lineage during development. Although gene targeting
studies in the mouse have essentially established the regula-
tory hierarchy for the MyoD family of proteins (see review,
[7]), very little is known about the regulation of the myogenic
bHLH proteins themselves or how their function is regulated
in the dividing myoblast [4].
The MyoD family of bHLH proteins are transcription fac-
tors that form heterodimers with ubiquitously expressed mem-
bers of the E-protein family, E12/47, E2-2, E2-5 and HEB,
and bind to a DNA consensus CANNTG, known as an E-
box, found in the promoters of several muscle-speci¢c genes
[11,12]. Even though MyoD and myf-5 are expressed in divid-
ing myoblasts [13], their function is kept in check and only
when the myoblast has withdrawn from the cell cycle upon
mitogen reduction are muscle-speci¢c genes activated. This
implies that there are regulatory mechanisms that control
myogenic factor function by sensing the cell cycle status of
the myoblast as it responds to growth factors and external
signals.
Here we discuss evidence from our own work and others as
to how the myogenic bHLH proteins are functionally regu-
lated during myoblast proliferation and how the activation of
MyoD and the myogenic program is coupled to exit from the
cell cycle.
2. MyoD function and growth control
In the initial characterization of the MyoD protein Lassar
and coworkers reported that MyoD appeared to antagonize
cell growth since the G418 resistant transformation frequency
for 10T1/2 ¢broblasts co-transfected with a MyoD expression
plasmid was about 1/10 that of the controls [14]. It was con-
cluded that the reduced transformation frequency was due to
the fact that MyoD committed recipient cells to myogenesis
and withdrawal from the cell cycle. This interpretation was
further supported by the observation that basic ¢broblast
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growth factor (LFGF), included in the medium to promote
continued proliferation, increased transformation frequency
to control levels. It was later shown that MyoD could induce
growth arrest in normal and transformed cells independent of
di¡erentiation and that the e⁄ciency of growth arrest was
dependent upon the level of MyoD expression in the target
cells [15,16]. In these initial studies the growth inhibitory e¡ect
was mapped to the DNA-binding and dimerization region of
MyoD (the bHLH domain) but mutants with alterations in
the basic region that did not bind DNA were also capable of
inhibiting cell growth almost as e⁄ciently as normal MyoD.
This result was not explained at the time but suggested that
speci¢c DNA-binding and gene activation were not necessary
to e¡ect growth arrest. We had also shown that the myogenic
conversion of 10T1/2 cells by avian MyoD (CMD1) was de-
pendent upon the level of MyoD expression: overexpression
of MyoD with the Rous sarcoma virus (RSV) promoter re-
sulted in di¡erentiated single myocytes whereas expression of
MyoD under the control of the weaker SV40 promoter pro-
duced a myogenic cell line that could divide while expressing
low levels of MyoD [8^10].
A great deal of work has focused on the transition from the
G0 to G1 state and the response of the quiescent cell to
growth signals that trigger replication (see review, [17]). This
transition involves the activation of the G1 cyclins (D1, D2,
D3, A and E) and the regulatory subunits for the G1 cyclin-
dependent kinases (cdks) (cdk4, cdk6 and cdk2) (see review,
[18]). The activation of the cyclins is a primary response in the
initiation of the cell cycle. Previous work has established that
cyclin D1 is the predominant cyclin that controls the rate of
progression through the G1 phase of the cell cycle and that
virtually all of the cyclin D1-dependent kinase activity is at-
tributable to cdk4 in mouse ¢broblasts [19,20].
The myogenic bHLH factors activate muscle-speci¢c gene
transcription only in cells cultured in low-mitogen medium.
Their activity is suppressed when myoblasts are cultured in
high serum medium or medium containing peptide growth
factors, such as transforming growth factor-L (TGF-L) or
LFGF [21^25]. The underlying mechanisms responsible for
the inhibition of di¡erentiation by these agents are complex
and depend a great deal on cell background. Although myo-
genic cultures inhibited from di¡erentiating by treatment with
LFGF and TGF-L show reduced expression from the MyoD
gene, additional regulatory pathways must be involved since
ectopic expression of MyoD does not override this inhibition
induced by the growth factors [26]. This result was interpreted
to mean that some sort of post translational mechanism con-
trols the activity of the MyoD family of muscle-speci¢c gene
regulators. In a similar fashion the oncogene Ras p21-val also
inhibits myogenesis without a¡ecting the DNA-binding or
transcriptional activity of either MyoD or MRF4 towards
an E-box reporter [27]. Quail primary muscle cells trans-
formed with RSV are blocked for muscle structural gene ex-
pression but continue to express MyoD mRNA, again imply-
ing a post transcriptional regulation of MyoD function in the
presence of v-src [28]. Likewise c-myc inhibits the MyoD and
myogenin initiated di¡erentiation of NIH3T3 even in the pres-
ence of ectopic MyoD expression so post translational regu-
lation of MyoD function is again implied [29].
Several models based upon various experimental ap-
proaches have been put forth to explain how the activity of
MyoD might be suppressed in the dividing myoblast [30^33].
The ¢rst model, proposed by Olson and colleagues, relied on
the observation that a conserved threonine residue in the basic
region of all the myogenic factors was essential for activity.
This threonine was also a consensus site for protein kinase C
(PKC) phosphorylation in vitro, a kinase activated by LFGF
[32]. This threonine in the myogenin basic region could be
phosphorylated in COS cells co-transfected with a PKC ex-
pression vector and mutation of this threonine to an aspara-
gine, which did not completely inactivate myogenic activity,
resulted in a myogenin that was now refractile to LFGF in-
hibition. This result was consistent with the idea that LFGF
triggered the phosphorylation of the basic region’s essential
threonine to block myogenin DNA-binding activity, and by
extension, activity of all the myogenic factors. However, sub-
sequent work by Konieczny’s group demonstrated that ectopi-
cally expressed MRF4 isolated from myoblasts treated with
LFGF, TGF-L or co-transfected with a PKC expression vec-
tor contained no detectable phosphothreonine [34]. Given
these results, it is currently considered unlikely that LFGF
and TGF-L inhibit the activity of the myogenic factors
through the direct PKC-dependent phosphorylation of the
basic region but rather block activity via an indirect mecha-
nism. An alternative explanation would require that myogenin
is regulated di¡erently than MRF4 even though they have the
identical threonine in the basic region that is phosphorylated
by PKC but this has not been resolved.
Benezera and colleagues identi¢ed the ¢rst member of a
novel class of dominant negative HLH proteins lacking the
basic region, known as Id1 for inhibitor of di¡erentiation,
that was shown to dimerize preferentially to the ubiquitously
expressed bHLH E-proteins (E12/47, E2-2, E2-5, and HEB) to
block heterodimer formation and myogenic factor activity
[30]. Id1 is expressed in dividing myoblasts where it presum-
ably binds to the E-proteins to prevent their interaction with
the myogenic factors MyoD or myf-5. Id1 mRNA expression
is greatly reduced in di¡erentiating muscle cultures so it was
proposed that the relative levels of Id1 and E-protein could
control the activity of the myogenic factors through compet-
itive dimerization. Unexpectedly, forced expression of Id1 in
myoblasts attenuated di¡erentiation but did not prevent myo-
genesis as Id protein is apparently degraded under di¡erentia-
tion conditions. A complication with the Id/E-protein stoichi-
ometry model comes from the observation that the protein
levels for Id1^4, as determined by Western blot analysis, are
substantially lower than for the total E-proteins expressed in
C2C12 myoblasts (Paterson, unpublished observations) mak-
ing a direct titration e¡ect unlikely. Although both Id1 and
Id3 are required for neurogenesis (as reported in the double
knockout mouse) any corresponding defects in muscle devel-
opment were not noted, so the role for Id1 and Id3 in myo-
genesis is not clear [35]. Unlike Id1 and Id3, Id2 is a retino-
blastoma protein (Rb) target that overrides the inhibitory
activities of Rb when activated by the Myc oncoproteins
and participates in neural tumor formation [36]. However,
Id2 is not expressed in di¡erentiating skeletal muscle during
embryogenesis or in adult muscle so it is unlikely to be an Rb
or E-protein regulator in myogenesis [36,37]. Peptide growth
factors and phorbol ester induce Id expression in C2C12 myo-
blasts so the Id proteins may play some role in the regulation
of MyoD function in the dividing myoblast but their exact
role will require further study [38].
Genes that respond rapidly to growth stimuli, the immedi-
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ate early genes (myc, jun and fos), also repress myogenic
factor function and expression [29,39^41]. In addition, peptide
growth factors and phorbol esters induce PKC, an activator
of cJun and cFos [42]. Initial studies suggested that the leucine
zipper of the bZip protein cJun interacted directly with the
bHLH domain of MyoD to suppress myogenic activity [39].
Subsequent studies, however, clearly demonstrated the amino-
terminal region of cJun without the leucine zipper inhibited
myogenesis as e⁄ciently as full size cJun so the bZip domain
was not involved in the inhibitory interaction [41].
The discovery that MyoD function involved the participa-
tion of the histone acetylase (HAT) and co-activator p300
suggested that p300 itself could be a target for the regulation
of MyoD activity [43^45]. E12 alone also interacts with p300
in reporter and protein interaction assays, consistent with the
idea that the heterodimer is subject to co-activation by p300
in vivo [46]. In fact, antibodies to p300 injected into myoblasts
blocked the MyoD activation of muscle-speci¢c reporters, cell
cycle withdrawal and myogenesis [43,44]. However, it now
appears that p300 acts as a sca¡old for another HAT, P/
CAF, and it is the HAT activity of P/CAF that is important
for the myogenic activity of MyoD [47^49]. Injection of P/
CAF antibodies into C2C12 muscle cells also inhibited di¡er-
entiation. Only deletions in P/CAF that remove HAT activity
blocked myogenesis but HAT deletions in p300 had no e¡ect.
P/CAF also acetylates MyoD in vitro and replacement of the
acetylated lysine residues with arginines reduced reporter ac-
tivation substantially but this had little e¡ect on DNA-bind-
ing in vitro with or without E12 [47]. The disparity between
DNA-binding and reporter activation suggests the acetylated
domain adjacent to the MyoD basic region may interact with
additional transcriptional activators yet to be identi¢ed. p300
also serves as a co-activator for another class of transcription
factors essential for myogenesis, the serum response factor-
related myocyte enhancer factor 2 (MEF2) family of proteins
[46,50]. Four members of this family have been identi¢ed in
the vertebrates to date, MEF2A^D (reviewed in [51]). Muta-
tional studies in Drosophila, where there is a single related
gene called DMEF2, have shown that DMEF2 is essential
for myogenesis but its interaction with Drosophila p300 has
not been formally described as a prerequisite for myogenesis
in the £y [52,53].
Induction of the proto oncogenes cJun and Fos, either by
peptide growth factors or by the co-transfection of cJun and
Fos expression plasmids during myogenesis, blocks terminal
muscle cell di¡erentiation by inhibiting the activity of MyoD.
This does not involve a direct interaction with the myogenic
factor, as mentioned earlier. The adenovirus oncoprotein E1A
inhibits the activities of cJun and JunB by targeting their
physical interaction with p300 [54]. We have recently deter-
mined that a similar mechanism is involved in the inhibition
of myogenesis by cJun (Zhao, Wei, and Paterson, unpublished
observations). The MyoD transactivation of muscle-speci¢c
reporters can be suppressed by a 78 amino acid domain
from the N-terminus of cJun through direct physical interac-
tion with p300 on a site shown to also bind MyoD (amino
acids 1514^1922). This N-terminal region in cJun does not
include either the delta domain [55] or the JNK phosphory-
lation sites on serines 63 and 73 [56] and is absent from JunD,
a member of the jun family that does not inhibit myogenesis
[41]. Ectopic expression of the 78 amino acid domain disrupts
MyoD interaction with p300 in the mammalian two-hybrid
system and blocks activation of muscle-speci¢c reporters,
myogenic conversion of 10T1/2 cells by MyoD, and myogen-
esis in C2C12 muscle cells. Co-expression of p300 can restore
normal reporter activity, e⁄cient myogenic conversion and
normal myogenesis in C2C12 cells, suggesting p300 itself is
the limiting factor in the cJun^p300 interaction. cJun residues
Ser 63/73 are apparently not required for interaction of this 78
amino acid peptide with p300, as reported for cJun interaction
with CBP [57], highlighting possible di¡erences in the co-fac-
tor function of CBP and p300. Therefore, peptide growth
factors cannot only regulate myogenesis by modulating cell
cycle decisions but also by disrupting the essential interaction
between MyoD and it co-activator, p300, through the induc-
tion of the proto oncogene cJun.
3. MyoD function and the cell cycle
A great deal of evidence from in vitro studies as well as
from the characterization of naturally occurring mutations
has demonstrated that the Rb is a key regulator of the cell
cycle and in the ability of cells to enter and remain in the G0
state (see review, [58]). The phosphorylation status of Rb and
the cycling state of the cell are directly correlated. Hypophos-
phorylated Rb is correlated with lack of cell growth, repres-
sion of genes involved in DNA replication and the di¡erenti-
ated state of a variety of cell types. Hyperphosphorylated Rb
is correlated with cell growth. The viral oncoproteins from
adenovirus (E1A), SV40 (T-antigen), and papillomavirus
(E7) interact with hypophosphorylated Rb to block growth
suppression and di¡erentiation in a variety of systems, includ-
ing muscle [59^61]. The HLH protein Id2 also binds to hypo-
phosphorylated Rb to block Rb function but its mRNA is
apparently not expressed in developing muscle, suggesting
the protein is also absent [36,62]. In Rb3/3 Saos cells
MyoD does not arrest proliferation, but once wild-type Rb
is restored to these cells, MyoD arrests growth [31]. This was
interpreted to suggest that MyoD and Rb were acting in the
same regulatory pathway. In vitro binding and immunopreci-
pitation studies demonstrated a MyoD/Rb interaction. This
result suggested that a direct MyoD/Rb interaction blocked
Rb phosphorylation and led to the suppression of myoblast
cell growth, cell cycle exit and di¡erentiation. The fact that T-
antigen peptide can compete the observed MyoD/Rb interac-
tion and that MyoD/Rb complexes can also be immunopre-
cipitated from muscle cell extracts supported this interpreta-
tion [31]. Lassar and associates have recently further de¢ned
the role of Rb in cell cycle arrest during skeletal muscle di¡er-
entiation [63]. Their ¢ndings indicate that Rb promotes myo-
genesis by inhibiting cell cycle progression and cooperating
with MyoD to activate the transcriptional activation domain
(TAD) of MEF2. Although it is unclear how MyoD activates
the MEF2 TAD, the process requires Rb and the phosphor-
ylation of Ser 387 in the MEF2 TAD. This synergy between
MyoD and MEF2 does not require the MADS domain, a
region in MEF2 previously suggested to interact with MyoD
in transcriptional activation [64]. In cell cycle control during
myogenesis Rb emerges as a key player and the function of
Rb is regulated by the G1 cyclins and their associated kinases,
cdk4 [65] and cdk6 [18]. However, the physiological targets for
Rb in muscle have yet to be identi¢ed.
A key set of experiments reported by Kohtz and associates
demonstrated that the activation of muscle gene transcription
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in di¡erentiating skeletal muscle myoblasts could be inhibited
by the ectopic expression of cyclin D1, but not cyclins A, B1,
B2, C, D3 and E [66]. Cyclin D1 also inhibited reporter acti-
vation by myogenin mutated in threonine 87, the PKC phos-
phorylation site conserved in all the myogenic bHLH factors,
indicating phosphorylation of this site is not relevant to the
mechanism of cyclin D1 inhibition. As mentioned earlier, vir-
tually all of the cyclin D1 kinase activity is attributable to
cdk4 in cultured mouse ¢broblasts and this is likely to be
the case in muscle cells. Experiments along similar lines by
Lassar and coworkers con¢rmed that forced expression of
cyclin D1 inhibited myogenesis and this correlated with the
apparent increased phosphorylation of MyoD, independently
of Rb phosphorylation [33,67]. In this instance ectopic expres-
sion of the cdk inhibitors (CKIs) p16 and p21 could augment
the di¡erentiation of subcon£uent C2C12 myoblast cultures
and suggested a block of cdk kinase activity would prevent
inhibition of MyoD function in proliferating cells. This lead
the authors to conclude MyoD might be a direct target for G1
cdk kinases, an area of interest to our own studies on the role
of phosphorylation in the regulation of MyoD heterodimer
formation with E12 [68].
4. G1 cdks and the regulation of MyoD
The implied phosphorylation of MyoD by cdk4 suggested
these two proteins might interact directly. To determine
whether MyoD bound cdk4 we initially looked at interactions
between cdk4/cyclin D1 produced in the baculovirus system
and MyoD produced in Escherichia coli [69]. The cdk4/cyclin
D1 produced in baculovirus-infected sf9 cells speci¢cally
phosphorylates a GST Rb target and this phosphorylation is
inhibited by the cdk4-speci¢c inhibitor p16 [70]. Using GST
fusions of all the myogenic factors, only baculovirus produced
cdk4/D1 speci¢cally bound to MyoD. GST fusions of E12 or
E47, the heterodimeric partner proteins for these factors in
vivo, did not bind cdk4/D1. Although MyoD bound to the
cdk4/cyclin D1 complex, it did not bind to cyclin D1 alone
but only to cdk4. This suggested MyoD did not dissociate the
active kinase and bound only to the catalytic subunit. More
importantly, it suggested the active kinase was not required
for interaction with MyoD. Co-expression of various combi-
nations of MyoD, cdk4 and cyclin D1 in the baculovirus
system and immunoprecipitation analysis of the complexes
formed con¢rmed the result that only MyoD and the catalytic
subunit of cdk4 were necessary for interaction and this could
occur in vivo as well. Further in vivo studies using the mam-
malian two-hybrid system and direct co-immunoprecipitations
from myoblast extracts con¢rmed that MyoD, but not myo-
genin, interacts with the catalytic subunit of cdk4 and that a
MyoD/cdk4/cyclin D1 complex could be isolated from divid-
ing myoblasts but not myotubes, respectively.
To determine if a MyoD cdk4 interaction could disrupt
MyoD function we ¢rst looked at MyoD DNA-binding activ-
ity. Surprisingly, increasing amounts of cdk4 could speci¢cally
disrupt DNA-binding of both MyoD homodimers and
MyoD/E12 heterodimers [69]. Importantly, cdk4 did not dis-
rupt the interaction of myogenin or myogenin/E-protein com-
plexes with DNA under the same conditions. Disruption of
MyoD DNA-binding did not require the active kinase since
cdk4 alone could inhibit the interaction with DNA. Since
cdk4 is expressed at similar levels in both myoblasts and myo-
tubes [33,66] this result suggested that cdk4 would likely not
be present in myotube nuclei to potentially disrupt MyoD
function. In dividing myoblasts both cyclin D1 and cdk4 are
nuclear, but in well-formed myotubes cyclin D1 is absent and
cdk4 is in the cytoplasmic compartment of newly di¡erenti-
ated muscle, as postulated. Cyclin D1 is the mitogen sensor
and the limiting factor in the assembly of active cdk4/cyclin
D1 complexes and it is absent in di¡erentiated myotubes [71].
Ectopic expression of a stable cyclin D1 (T286A) was induced
in myotubes to see if cdk4 would relocate to myotube nuclei
[72]. Induction of stable cyclin D1 resulted in the nuclear
compartmentalization of cdk4 in myotubes. This was the ¢rst
hint that the regulation of cyclin D1 levels by mitogens could
possibly impact nuclear MyoD function by regulating the cel-
lular localization of cdk4. This hypothesis turned out to be
correct since the forced nuclear localization of cdk4 in the
absence of cyclin D1 blocked expression from a MyoD acti-
vated reporter but not activation of the same reporter by
myogenin. In addition, reporter inhibition did not depend
upon cdk4 kinase activity since cdk4 that was inactive (i.e.
it could not be phosphorylated by cdk activating kinase or
CAK) [70] also blocked reporter activation by MyoD but not
myogenin. Consistent with this result, conversion of 10T1/2
¢broblasts by MyoD was also inhibited in a dose-dependent
fashion by ectopic expression of both wild-type and inactive
cdk4 with a nuclear localization signal (NLS). Active cdk4
without an NLS only blocked myogenesis in growth medium
since nuclear localization under these conditions depends
upon mitogens and cyclin D1. This result coupled the cell
cycle and myogenesis through a cyclin D1-dependent interac-
tion between MyoD and cdk4 and provided a mechanism to
keep MyoD inactive in the dividing myoblast. The speci¢c
MyoD^cdk4 interaction in dividing myoblasts, coupled with
the cyclin D1-dependent nuclear targeting of cdk4, suggested
a mitogen-sensitive mechanism whereby cyclin D1 can regu-
late MyoD function and the onset of myogenesis by control-
ling the cellular location of cdk4 rather than the phosphory-
lation status of MyoD [69].
Using the mammalian two-hybrid system in C2C12 cells we
were unable to detect any interaction between Rb and either
MyoD or myogenin in dividing or di¡erentiated cells [73].
However, both MyoD and Rb interacted strongly with E12
and E2F, respectively, under both conditions. Therefore, in
this type of in vivo assay no evidence for an Rb interaction
with the myogenic factors could be detected, in contrast to the
in vitro studies by Gu, Nadal-Ginard and coworkers [31]. It is
clear, however, that Rb promotes the expression of late myo-
genic markers by cooperating with MyoD to switch on the
TAD of MEF2 and to inhibit cell cycle progression [63]. With
regard to the latter issue, Caruso and associates reported that
MyoD activates the Rb promoter in di¡erentiating myoblasts
and have proposed this as an additional mechanism to pro-
vide excess hypophosphorylated Rb to block cell growth [74].
It is interesting to speculate that hypophosphorylated Rb may
transcriptionally activate additional genes in the post mitotic
myoblast, which in turn may be necessary to trigger the late
myogenic program. It is still not known if all Rb in di¡er-
entiated myotubes is inactive or in association with the his-
tone deacetylase transcriptional repressors such as HDAC1
[75].
MyoD interacts with cdk4 through a conserved 15 amino
acid domain in the C-terminus of MyoD [73]. Surprisingly,
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full MyoD, the C-terminus beyond the bHLH region, or just
the 15 amino acid cdk4-binding domain all inhibit cdk4 phos-
phorylation of an Rb target in vitro, whereas myogenin does
not. Expression of only the MyoD 15 amino acid cdk4-bind-
ing domain in vivo fused either to GFP or GST with an NLS
blocks Rb phosphorylation, inhibits cell growth and promotes
di¡erentiation of C2C12 cells in growth medium. In a func-
tional assay, MyoD deleted in the C-terminus beyond the
bHLH region cannot rescue the defective myogenic phenotype
in BC3H1 cells but the addition of just the 15 amino acid
cdk4-binding domain to the deleted MyoD restores the nor-
mal myogenesis seen with full MyoD. Rescue is not seen with
p16 or p21, thus inhibition of cdk4 is not the mechanism
responsible for the rescue observed with the addition of the
MyoD cdk4-binding region. This domain has some other
function in the context of MyoD yet to be determined. We
have proposed that a regulatory check point in the terminal
cell cycle arrest of the myoblast during di¡erentiation involves
the modulation of the cyclin D1 cdk-dependent phosphoryla-
tion of Rb through the opposing e¡ects of cyclin D1 and
MyoD. This modulation is critically dependent upon the reg-
ulation of the cyclin D1 gene through various pathways that
respond to cellular growth signals [69,73].
5. Cyclin D1 regulation and myogenesis
A key factor in the regulation of cell cycle withdrawal dur-
ing terminal di¡erentiation of the myoblast that is implicit
from the MyoD^cdk4 interaction we have described is the
control of the cyclin D1 gene and the concomitant regulation
of nuclear cdk levels. Peptide growth factors or high concen-
trations of serum in growth medium increase cyclin D1
mRNA and protein levels but the precise molecular mecha-
nisms underlying this activation have only recently come to
light [18]. Members of the AP-1 family of transcription fac-
tors, cJun and fos, are well-documented in their role as tran-
scriptional mediators in various cellular contexts after mito-
genic stimulation or exposure to stress but their role in normal
cell growth is less understood [42]. Studies of the cJun de¢-
cient mouse have shown that the basal levels of AP-1 (a cJun
and fos heterodimer) activity are essential for survival and
mediate not only response to environmental stimuli but also
play a critical role in normal cell cycle progression [76^78]. In
this last instance recent studies have shown that AP-1 regu-
lates G1 progression through its control of cyclin D1 gene
expression [77] and that p300 is a co-activator for AP-1 in
the context of the cyclin D1 promoter [76]. Using cJun3/3
¢broblasts, it has been shown recently that cJun negatively
regulates the transcription of p53 and its target gene, the
CKI, p21, providing a further link between mitogenic signal-
ing and cell cycle control [79]. Thus cJun not only inhibits
MyoD interaction with its co-activator, p300, but it also is
required to activate the cyclin D1 gene and reduce levels of
the CKI, p21, to promote continued growth.
NF-Ub is also a positive mediator of cell growth and has
recently been shown to directly regulate the cyclin D1 pro-
moter in C2C12 myoblasts and embryonic ¢broblasts [80,81].
NF-Ub expression can inhibit myogenic di¡erentiation by di-
rectly activating cyclin D1 expression whereas myoblasts that
lack NF-Ub, induced in this instance by NF-Ub antisense
methods, display a reduction in proliferation and exit the
cell cycle more rapidly than control cells [80]. Thus the ability
of NF-Ub to control cellular proliferation and di¡erentiation
are tightly coupled to the regulation of the cyclin D1 gene.
L-Catenin is not only a structural component of adherence
junctions but is also a co-factor in transcription activation
complexes with members of the lymphoid enhancing factor
family (LEF-1). Elevated L-catenin levels in colorectal cancer
caused by mutations in either L-catenin or in the adenomatous
polyposis coli protein, which regulates the degradation of
L-catenin, result in the increased formation of transcription-
ally active L-catenin/LEF-1 complexes [82,83]. The increased
transcription of unknown target genes results in uncontrolled
cell growth. The cyclin D1 gene was shown recently to be a
target for L-catenin/LEF-1 activation through a LEF-1-bind-
ing site in the promoter [84,85]. This is the same region that is
transcriptionally repressed by caveolin-1, a protein that has
recently been shown to inhibit the cyclin D1 promoter [86].
Thus regulation of MyoD function during development
through the wingless/wnt pathway [87] could involve the reg-
ulation of the cyclin D1 gene via the activity of L-catenin, a
known target for wingless/wnt activation [88].
Increasing evidence, as brie£y described here, points to the
conclusion that the regulation of the cyclin D1 gene plays a
central role in modulating cell growth during development
and di¡erentiation as well as in the onset of various types
of cancer [89].
6. Myogenesis and the CKIs
Progression through the G1 phase of the cell cycle is closely
modulated by a family of cdks, cdk4 and cdk6, whose activ-
ities are in turn constrained by a group of proteins known as
the CKIs (see review, [90]). The CKIs are divided into two
groups based upon their structure and cdk targets. The ¢rst
group is know as the INK4 proteins since they bind speci¢-
cally to and inhibit the catalytic subunit of cdk4 and cdk6 and
include p15, p16, p18, and p19. The second group, the cip/kip
family, bind to the cyclin D-, A- and E-dependent kinases via
both the cyclin and catalytic subunits and include p21, p27
and p57. It has been shown in transfection studies that MyoD
can upregulate the promoter for the CKI p21, implying sim-
ilar regulation during cell cycle exit in myogenesis [91]. How-
ever, mice lacking both MyoD and myogenin genes have nor-
mal expression patterns of p21 and mice lacking the p21 gene
develop normally, suggesting that the role of p21 in myogen-
esis is either redundant or minor [92]. Interestingly, mice lack-
ing both p21 and p57 fail to form myotubes and myoblasts
show increased proliferation and apoptosis, suggesting that
p21 and p57 redundantly play a role in skeletal muscle termi-
nal cell cycle withdrawal [93]. p57 is predominantly expressed
in di¡erentiated tissues, and the 7 kb mRNA for this inhibitor
is only detectable in skeletal muscle and heart, so its impor-
tance in cdk regulation in muscle may be dominant compared
with p21 [94]. Unexpectedly, the p21 and p27 CKIs are also
essential activators of cyclin D-dependent kinases in mouse
¢broblast [95]. p21/p27 remain associated with cyclin D^cdk4
in an active kinase complex and are liberated later in the cell
cycle to inhibit cyclin E/cdk2. Both p21 and p27 are required
for the assembly and nuclear import of cyclin D1/cdk4 and
their participation in this process is though to provide the
nuclear import signal that is lacking in the kinase.
The calcium-binding protein calmodulin is also a key regu-
lator of the cell cycle [96]. Recent studies have shown that
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calmodulin is essential for cdk4 activity and the nuclear accu-
mulation of cyclin D1^cdk4 complexes during G1 [97] and
that this accumulation likely involves Hsp90.
7. Conclusion
Although the identi¢cation and characterization of the
MyoD bHLH family of myogenic regulators has enhanced
our understanding of muscle formation during development,
little is known about transcriptional control or the functional
regulation of these factors during this process: what activates
the myogenic regulatory genes at the appropriate time during
development and how is their functional activity regulated by
environmental cues that modulate cell growth and trigger dif-
ferentiation? Here we have presented a brief overview of some
of the regulatory mechanisms that regulate skeletal muscle cell
growth, cell cycle withdrawal and di¡erentiation and how
these various stages in development impact the regulation of
MyoD function (Fig. 1). The new observation that MyoD
interacts with the G1 cdks to regulate Rb function and cell
growth provides an explanation for several results that have
raised more questions than answers in earlier studies. Now it
is clear that signaling pathways that induce cyclin D1, a key
regulator of cell cycle progression (see review, [89]), also in-
duce increased levels of nuclear cdk4 which, in turn, inhibits
MyoD function in the dividing cell. Functional MyoD, liber-
ated from cdk inhibition upon the reduction in cyclin D1
levels in response to decreased mitogen signaling, activates
myogenesis as well as genes that maintain cell cycle exit,
such as p21 and Rb. Overexpression of MyoD blocks existing
cdk4 to trigger growth arrest and this only depends upon the
15 amino acid cdk4-binding domain in the C-terminus of
MyoD. Our preliminary studies indicate that the MyoD
cdk4-binding domain also interacts with cdk6 [98] and cdk2
[99,100], the other major G1 cdks, so inactivation of MyoD
by sequestration throughout G1 to get past the check point
can certainly occur in the dividing myoblast. It is not yet
known if MyoD interaction with cdk2 and cdk6 behaves ex-
actly like cdk4 but cdk6 is cytoplasmic in myotubes and can
be relocated to nuclei in response to the induction of stable
cyclin D1 in myotubes just like cdk4. This is not unexpected
since cdk4 and cdk6 are s 70% identical at the amino acid
level. The direct interaction between MyoD and the G1 cdks
provides a novel mechanism for the regulation of MyoD func-
tion that is tightly regulated by the growth status of the cell
through the expression of the cyclin D1 gene. Clearly there are
redundant mechanisms involved in the regulation of di¡eren-
tiation and exit from the cell cycle and no doubt di¡erent
themes will emerge as this process is explored further.
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